Medikamentöse Therapie der Herzinsuffizienz bei Älteren

Schlüsselwörter

Herzinsuffizienz - Alter - medikamentöse Therapie - erhaltene Pumpfunktion

Keywords

heart failure - elderly - medical therapy - preserved pump ejection fraction

• Literatur

• 1 Bangalore S, Kumar S, Messerli F. When Conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist?. Congest Heart Fail 2012; Dec 12. doi: [Epub ahead of print]
• 2 Baruch L, Glazer R, Aknay N et al. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). Amer Heart J 2004; 148: 951-957
• 3 Cleland J, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Europ Heart J 2006; 27: 2338-2345
• 4 Conraads V, Metra M, Kamp O et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012; 14: 219-225
• 5 Dulin B, Haas S, Abraham W et al. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Amer J Cardiol 2005; 95: 896-898
• 6 Felker M, Lee K, Bull D et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797-805
• 7 Flather M, Yusuf S, Køber L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575-1581
• 8 Flather M, Shibata M, Coats A et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225
• 9 Komajda M, Hanon O, Hochadel M et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 2009; 30: 478-486
• 10 Loncar G, von Haehling S, Tahirovic E et al. Effect of beta blockade on natriuretic peptides and copeptin in elderly patients with heart failure and preserved or reduced ejection fraction: Results from the CIBIS-ELD trial. Clin Biochem 2012; 45: 117-122
• 11 Mantziari L, Guha K, Khalique Z et al. Relation of dosing of the renin–angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis. Am J Cardiol 2012; 109: 1619-1625
• 12 Massie B, Carson P, McMurray J et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-67
• 13 McMurray J et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-1847
• 14 Whitbeck M, Charnigo R, Khair P et al. Increased mortality among patients taking digoxin - analysis from the AFFIRM study. Eur Heart J 2012; Nov 27. [Epub ahead of print], doi:
• 15 Yusuf S, Pfeffer M, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARMPreserved trial. Lancet 2003; 362: 777-781
• 16 Zannad F, McMurray J, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21